Detection of clinically silent brain lesions in [18F]FDG PET/CT study in oncological patients: analysis of over 10,000 studies.
Adult
Aged
Aged, 80 and over
Asymptomatic Diseases
Brain
/ diagnostic imaging
Brain Neoplasms
/ diagnostic imaging
Breast Neoplasms
/ pathology
Diagnosis, Differential
Female
Fluorodeoxyglucose F18
Humans
Lung Neoplasms
/ pathology
Male
Middle Aged
Neuroimaging
Positron Emission Tomography Computed Tomography
Retrospective Studies
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 09 2021
14 09 2021
Historique:
received:
11
06
2021
accepted:
30
08
2021
entrez:
15
9
2021
pubmed:
16
9
2021
medline:
17
12
2021
Statut:
epublish
Résumé
The study aimed to show that including the brain region into the standard 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) study protocol may result in detecting clinically silent brain tumours. We retrospectively analyzed the group of 10,378 from the total of 12,011 consecutive patients who underwent the torso and brain [18F]FDG PET/CT scanning, considering an ability of the method to evaluate undetected before brain tumours in patients diagnosed and treated in our institution. While collecting the database, we followed the inclusion criteria: at least 1-year of follow-up, a full medical history collected in our institution, histopathologic examination or other studies available to confirm the type of observed lesion, and the most importantly-no brain lesions reported in the patients' medical data. In this study, performing the torso and brain [18F]FDG PET/CT imaging helped to detect clinically silent primary and metastatic brain tumours in 129 patients, and the benign lesions in 24 studied cases, in whom no suspicious brain findings were reported prior to the examination. In conclusion, including the brain region into the standard [18F]FDG PET/CT protocol can be considered helpful in detecting clinically silent malignant and benign brain tumours.
Identifiants
pubmed: 34521979
doi: 10.1038/s41598-021-98004-w
pii: 10.1038/s41598-021-98004-w
pmc: PMC8440628
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18293Informations de copyright
© 2021. The Author(s).
Références
BMC Med Res Methodol. 2012 Jun 19;12:81
pubmed: 22712852
Ann Nucl Med. 2013 Feb;27(2):163-9
pubmed: 23188388
Handb Clin Neurol. 2018;149:89-112
pubmed: 29307364
Nat Rev Clin Oncol. 2019 Aug;16(8):509-520
pubmed: 30733593
Biomed Res Int. 2014;2014:129683
pubmed: 25025032
Indian J Nucl Med. 2011 Apr;26(2):64-6
pubmed: 22174509
J Nucl Med Technol. 2010 Sep;38(3):123-7
pubmed: 20724533
Sci Rep. 2021 May 27;11(1):11239
pubmed: 34045576
Int J Mol Sci. 2019 Sep 20;20(19):
pubmed: 31547109
Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):e277-e283
pubmed: 33386279
Eur J Nucl Med Mol Imaging. 2009 Dec;36(12):2103-10
pubmed: 19838705
Brain Tumor Res Treat. 2018 Oct;6(2):47-53
pubmed: 30381916
Nucl Med Mol Imaging. 2019 Dec;53(6):374-381
pubmed: 31867072
Oncotarget. 2017 Jun 27;8(26):43536-43542
pubmed: 28402949
Diagnostics (Basel). 2020 Jun 17;10(6):
pubmed: 32560298
Hell J Nucl Med. 2017 May-Aug;20(2):113-121
pubmed: 28697187
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219